Jesús Manuel
González Santiago
Profesor Asociado CC. Salud
Hospital Universitario de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (10)
2024
-
Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition
Biochemical Pharmacology
-
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Alimentary Pharmacology and Therapeutics
2023
-
Splenosis as an incidental finding in a patient with multifactorial anemia
Revista espanola de enfermedades digestivas, Vol. 115, Núm. 4, pp. 188-189
-
Spontaneously ruptured hepatocellular carcinoma on non-cirrhotic liver: A prospective case series
Gastroenterologia y Hepatologia
2022
-
Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia
Hepatology, Vol. 76, Núm. 5, pp. 1259-1274
-
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study
Liver International, Vol. 42, Núm. 8, pp. 1891-1901
2021
-
Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics
Aging, Vol. 13, Núm. 19, pp. 23416-23434
-
Novel pharmacological options in the treatment of cholangiocarcinoma: Mechanisms of resistance
Cancers, Vol. 13, Núm. 10
2019
-
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
Journal of Hepatology, Vol. 71, Núm. 4, pp. 666-672
2017
-
Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection
International Journal of Clinical Practice, Vol. 71, Núm. 9